The single-site, first-in-human Phase I trial will assess whether the therapy can kill cancer cells in patients who have become resistant to Venclexta.
The University of Colorado Anschutz Gates Institute has received Investigational New Drug clearance from the U.S. Food and Drug Administration, marking the first chimeric antigen receptor (CAR) T-cell ...
A key cancer-fighting gene in leukemia is switched off—not broken—and scientists from The Jackson Laboratory (JAX) have found ...
The FDA granted orphan drug designation to a triggering receptor expressed on myeloid cells 1 peptide inhibitor for the ...
New data highlight the activity and safety of MRD-guided preemptive azacitidine in patients with myelodysplastic neoplasms or ...
As survival rates for female-specific cancers continue to rise, therapy-related myeloid neoplasms (t-MN) have become a ...
Hematopoietic stem cell (HSC) research over the past century has shown that leukemia may be driven by an invisible hand of inflammation. The bone marrow and inflammation, then, may hold the keys to ...
Umbilical cord blood stem cell microtransplantation combined with chemotherapy significantly prolonged disease-free survival (DFS) in patients with acute myeloid leukemia (AML) and high-risk ...
Shareholders approve acquisition of Aptose by Hanmi Pharmaceutical in “Go Private” transaction TUS+VEN+AZA triplet frontline therapy continues to ...
Shields Gazette on MSN
Wrap for Jak set to donate more than 2,100 Easter eggs across the North East
The Wrap for Jak team has secured more than 2,100 Easter Eggs for people in need.
A Winter Haven family is navigating an emotional and life-changing medical journey, as two young brothers fight the same rare ...
Chimeric antigen receptor T-cell therapy - CAR T for short - has been a major advance in treating blood cancers like leukemia ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results